ATE261307T1 - Verwendung von misoprostol und/oder misoprostolsäure zur behandlung von erektionsstörungen - Google Patents

Verwendung von misoprostol und/oder misoprostolsäure zur behandlung von erektionsstörungen

Info

Publication number
ATE261307T1
ATE261307T1 AT98913967T AT98913967T ATE261307T1 AT E261307 T1 ATE261307 T1 AT E261307T1 AT 98913967 T AT98913967 T AT 98913967T AT 98913967 T AT98913967 T AT 98913967T AT E261307 T1 ATE261307 T1 AT E261307T1
Authority
AT
Austria
Prior art keywords
misoprostol
erective
disorder
treat
misoprostolic
Prior art date
Application number
AT98913967T
Other languages
English (en)
Inventor
Panagiotis Kanakaris
Petros Karouzakis
Original Assignee
Panagiotis Kanakaris
Petros Karouzakis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panagiotis Kanakaris, Petros Karouzakis filed Critical Panagiotis Kanakaris
Application granted granted Critical
Publication of ATE261307T1 publication Critical patent/ATE261307T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT98913967T 1997-05-06 1998-04-22 Verwendung von misoprostol und/oder misoprostolsäure zur behandlung von erektionsstörungen ATE261307T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GR97100172 1997-05-06
PCT/GR1998/000012 WO1998050039A1 (en) 1997-05-06 1998-04-22 Use of misoprostol or/and misoprostol acid for preparing drug in order to cure erectile dysfunction

Publications (1)

Publication Number Publication Date
ATE261307T1 true ATE261307T1 (de) 2004-03-15

Family

ID=10942965

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98913967T ATE261307T1 (de) 1997-05-06 1998-04-22 Verwendung von misoprostol und/oder misoprostolsäure zur behandlung von erektionsstörungen

Country Status (10)

Country Link
US (2) US6210343B1 (de)
EP (1) EP0980245B1 (de)
JP (1) JP2001525803A (de)
AT (1) ATE261307T1 (de)
AU (1) AU6848098A (de)
DE (2) DE69822295T2 (de)
ES (1) ES2216279T3 (de)
GR (1) GR1002847B (de)
PT (1) PT980245E (de)
WO (1) WO1998050039A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1002847B (el) 1997-05-06 1998-01-27 Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως
US7087240B1 (en) * 1998-06-25 2006-08-08 Lavipharm Laboratories Inc. Device and method for the treatment of erectile dysfunction
GR1003199B (el) 1998-08-14 1999-09-01 Χρηση της μισοπροστολης ή και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση της σεξουαλικης δυσλειτουργιας στις γυναικες
US6825234B2 (en) 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
WO2000051978A1 (en) 1999-03-01 2000-09-08 Nitromed, Inc. Nitrosated and nitrosylated prostaglandins, compositions and metods of use
US7479120B2 (en) * 2002-02-22 2009-01-20 Hans Gregersen Method and apparatus for investigating force-deformation properties in muscles in walls of bodily hollow systems
US8287474B1 (en) 2002-08-22 2012-10-16 Koenig J Frank Method and apparatus for noninvasively increasing whole body blood flow and noninvasive physical exercise of limbs from the outside and from within the limb to treat diseases throughout the body
US7037257B1 (en) * 2002-08-22 2006-05-02 Koenig J Frank Erectile dysfuction treatments comprising momentary vacuum therapy alone or with medications
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
US20050255161A1 (en) * 2004-05-10 2005-11-17 Servet Buyuktimkin Method for the long term stabilization of labile compounds at room temperature in pharmaceutical preparations containing water
GB0417401D0 (en) * 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
US20060286172A1 (en) * 2005-06-03 2006-12-21 Anu Mahashabde Pharmaceutical compositions comprising prostanoid-receptor agonists and methods of making and using the same
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
JP2010095454A (ja) * 2008-10-14 2010-04-30 Cyclochem:Kk 抗菌組成物
WO2010070617A1 (en) * 2008-12-19 2010-06-24 Shimoda Biotech (Pty) Ltd Inclusion complexes of alpha-cyclodextrin and sildenafil salt
RU2428933C1 (ru) * 2010-02-19 2011-09-20 Государственное образовательное учреждение высшего профессионального образования "Рязанский государственный медицинский университет имени акад. И.П. Павлова Федерального агентства по здравоохранению и социальному развитию" Способ определения индекса функциональной достаточности артериального кровенаполнения кавернозной ткани по результатам ультрасонографии полового члена
RU2444989C1 (ru) * 2010-09-27 2012-03-20 Государственное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения и социального развития Российской Федерации (ГОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития России) Способ диагностики васкулогенной эректильной дисфункции
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
IT201600119871A1 (it) * 2016-11-25 2018-05-25 Sabatino Russo Uso dell’associazione di inibitori della fosfodiesterasi 5 con prostaglandina e1 per il trattamento della disfunzione erettile
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4696821A (en) 1983-10-11 1987-09-29 Warner-Lambert Company Transdermal delivery system for administration of nitroglycerin
US5256652A (en) 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
ZA912984B (en) 1990-04-25 1992-01-29 Alza Corp Treatment of erectile dysfunction
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
US5962528A (en) 1991-07-03 1999-10-05 Scott; Nathan Earl Prostaglandin E2 /F2α combination for treating impotence
AU2300092A (en) * 1991-07-03 1993-02-11 Nathan E. Scott Prostaglandin e2 treatment of impotence
US5252602A (en) * 1991-10-11 1993-10-12 Rafeul Alam Effects of misoprostol on allergic responses
BR9203277A (pt) * 1992-08-21 1994-03-01 Cesar Roberto Dias Nahoum Utilizaccao de drogas eretogenicas e respectivas metodologias de aplicacao
US5773457A (en) * 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions
US5324746A (en) 1993-02-12 1994-06-28 Mckee Rex N Method of treating damaged mucosal and epithelial tissues with misoprostol
US6007836A (en) 1993-05-28 1999-12-28 Vericade, Inc. Transdermal vasodilator
FR2710649A1 (fr) 1993-09-30 1995-04-07 Germinal Sarl Film polymérique à base de prolamines, son procédé de préparation et ses applications .
JP3901213B2 (ja) 1994-08-05 2007-04-04 インファルマ・ソシエテ・アノニム ホスファチジルコリンとプロスタグランジンｅ１及び／又はトロキサールチンとの複合体を含有する、勃起不能の局所治療のための製剤
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
CN1126587A (zh) 1995-01-10 1996-07-17 王怀秀 经阴囊睾酮缓释系统
CA2215307A1 (en) 1995-03-14 1996-09-19 Vivus, Incorporated Pharmaceutical compositions and kits for preventing erectile dysfunction
US5731339A (en) 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US5688499A (en) 1996-03-13 1997-11-18 Queen's University At Kingston Antagonism of endothelin actions
US5684177A (en) 1996-05-17 1997-11-04 Torcan Chemical Ltd. Misoprostol
GR1002847B (el) 1997-05-06 1998-01-27 Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως
US5976566A (en) 1997-08-29 1999-11-02 Macrochem Corporation Non-steroidal antiinflammtory drug formulations for topical application to the skin
CA2306837C (en) 1997-10-28 2007-05-08 Vivus, Inc. Treatment of female sexual dysfunction
US6046244A (en) 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
US6277884B1 (en) 1998-06-01 2001-08-21 Nitromed, Inc. Treatment of sexual dysfunction with N-hydroxyguanidine compounds
US5942545A (en) 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
WO2000032195A1 (fr) 1998-12-02 2000-06-08 Mochida Pharmaceutical Co., Ltd. Preparations destinees a etre administrees par voie uretrale
IL139941A0 (en) 1999-12-02 2002-02-10 Pfizer Prod Inc Use of prostaglandin agonists to treat erectile dysfunction or impotence
US6323241B1 (en) 2000-01-10 2001-11-27 Nexmed (Holdings) Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
US6476037B1 (en) 2000-03-23 2002-11-05 The Regents Of The University Of California L-arginine and phosphodiesterase (PDE) inhibitor synergism
WO2001070708A1 (en) 2000-03-23 2001-09-27 Merck & Co., Inc. Substituted piperidines as melanocortin receptor agonists
JP2003527444A (ja) 2000-03-23 2003-09-16 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体アゴニストとして作用するスピロピペリジン誘導体
KR20030019628A (ko) 2000-07-31 2003-03-06 오노 야꾸힝 고교 가부시키가이샤 프로스타글란딘 유도체를 유효 성분으로 하는 발기부전치료제

Also Published As

Publication number Publication date
US6589990B1 (en) 2003-07-08
WO1998050039A1 (en) 1998-11-12
US6210343B1 (en) 2001-04-03
DE69822295T2 (de) 2005-02-24
DE980245T1 (de) 2000-08-31
AU6848098A (en) 1998-11-27
GR1002847B (el) 1998-01-27
JP2001525803A (ja) 2001-12-11
PT980245E (pt) 2004-06-30
EP0980245A1 (de) 2000-02-23
ES2216279T3 (es) 2004-10-16
EP0980245B1 (de) 2004-03-10
DE69822295D1 (de) 2004-04-15

Similar Documents

Publication Publication Date Title
ATE261307T1 (de) Verwendung von misoprostol und/oder misoprostolsäure zur behandlung von erektionsstörungen
ATE209483T1 (de) Behandlung von multipler sklerose
EP0802782A4 (de) Prophylaktische und therapeutische behandlung von haupt sensibilisierung und -reizung
MX9306239A (es) Composicion farmaceutica que forma un gel de lecitina in vivo para la liberacion mantenida de un compuesto biologicamente activo y procedimiento para la preparacion de la misma.
ES2052733T3 (es) Dispositivo electroterapeutico de baja frecuencia.
DE69731467D1 (de) Verfahren zur erhaltung von bestehenden körperfettgehalt und/oder körpergewicht
EA199700213A1 (ru) Крем на водной основе для локального применения, способ его приготовления, способ лечения эректильной дисфункции у мужчин, способ лечения аноргазма у женщин, способ лечения микроваскулярных заболеваний и способ лечения ран или хирургических рассечений
EA199800694A1 (ru) Композиция, включающая ингибитор il-1 и гидрогелевый эфир, и способы ее применения
ATE233091T1 (de) Verwendung von histamine-2 agonisten zur behandlung sexueller funktionsstörungen
Franek et al. Modern application of high voltage stimulation for enhanced healing of venous crural ulceration
ATE172113T1 (de) Behandlung von zellgewebsentzündung mit retinoide
PT1173201E (pt) Metodo para o tratamento de fibrose utilizando um antagonista da subunidade alfa 4 de integrina
ATE138567T1 (de) Zusammensetzung und verfahren zur behandlung von schmerzvollen entzündlichen oder allergischen erkrankungen
NO994640D0 (no) Hostestillende midler
ATE414522T1 (de) Verfahren zur behandlung von akuter und durch übermässige beanspruchung verursachter zerrung und verstauchung mit hyaluronsäure
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
IS2147B (is) Notkun á blöndu díóls og alfa-hýdroxýsýru til að meðhöndla sjúkdóma sem lýsa sér í ofvexti í hornlagi húðþekju
ATE230609T1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
ATE297739T1 (de) Endothelin-antagonisten zur behandlung von herzversagen
PT1007093E (pt) Metodos para o tratamento de desordens atraves da utilizacao de interleucina-9 e seus antagonistas
DE69623316D1 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
Finalay et al. Short contact crude coal tar therapy for psoriasis
DE69635282D1 (de) Behandlung der exzessiven aggressivität mit olanzapine
RU94033628A (ru) Способ лечения остеоартроза
DE69430807D1 (de) Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0980245

Country of ref document: EP

REN Ceased due to non-payment of the annual fee